NEW YORK, December 10, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Viropharma Inc. (NASDAQ: VPHM), Santarus, Inc. (NASDAQ: SNTS), Cyberonics, Inc. (NASDAQ: CYBX), Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), and Dyax Corp. (NASDAQ: DYAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Viropharma Inc. Research Report
On December 5, 2013, Viropharma Inc.'s (Viropharma) stock declined 0.26%, ending the day at $49.59. Over the previous three trading sessions, shares of Viropharma gained 0.18% compared to the Nasdaq Composite which declined 0.30% during the same period. The Full Research Report on Viropharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/c730_VPHM
--
Santarus, Inc. Research Report
On December 5, 2013, Santarus, Inc. (Santarus) gained 0.06%, ending the day at $31.99. Over the previous three trading sessions, shares of Santarus declined 0.12% compared to the Nasdaq Composite which declined 0.30% during the same period. The Full Research Report on Santarus, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/22f8_SNTS
--
Cyberonics, Inc. Research Report
On December 5, 2013, Cyberonics Inc. (Cyberonics) announced that the Company's Board of Directors approved a new share repurchase program of one million shares. The announcement has come after the substantial completion of its prior share repurchase program. Cyberonics further informed that its Board of Directors had previously authorized repurchases of shares in February 2008, February 2010, June 2011, November 2011, and January 2013. Cyberonics expects the new authorization to commence shortly and also expects the same to be completed by the end of full-year FY 2015. The Company further reported that it has repurchased more than 4.2 million shares for approximately $152 million since February 2008 through December 3, 2013. The Full Research Report on Cyberonics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/ad51_CYBX
--
Pacira Pharmaceuticals, Inc. Research Report
On December 5, 2013, Pacira Pharmaceuticals Inc. (Pacira Pharmaceuticals) announced that the Company has submitted a Prior Approval Supplement (PAS) with the US Food and Drug Administration (FDA) for an additional bulk manufacturing suite for EXPAREL (bupivacaine liposome injectable suspension). Pacira Pharmaceuticals added that under the reauthorization of the Prescription Drug User Fee Act (PDUFA), the FDA established a 4-month PDUFA goal for approval of a manufacturing PAS. Pacira Pharmaceuticals anticipates a PDUFA date in early April 2014, should the FDA accept the PAS for review. The Full Research Report on Pacira Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/c0aa_PCRX
--
Dyax Corp. Research Report
On December 5, 2013, Dyax Corp. (Dyax) announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its drug candidate DX-2930, which is the Company's fully human monoclonal antibody inhibitor of plasma kallikrein, for use in the treatment of hereditary angioedema (HAE). According to the Company, it is developing DX-2930 to be a long-acting, prophylactic agent that prevents HAE attacks. The Company's development plans include a dosage formulation that will permit infrequent self-administration by small volume, subcutaneous injection. Gustav Christensen, President and CEO of Dyax, said, "Through our experience in the development and commercialization of KALBITOR (ecallantide), we have gained a deep understanding of the HAE market and patient needs. There is still a significant unmet medical need within the HAE community which we plan to address with DX-2930. Orphan drug designation is an important element of our development strategy for DX-2930 as we work to further improve the health and quality of life for individuals suffering from this painful and often debilitating condition." The Company further informed that DX-2930 is currently being studied in a placebo-controlled, dose-escalation Phase 1 trial in normal individuals, and the results from the study are expected in Q1 2014. The Full Research Report on Dyax Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/58ae_DYAX
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
